Annual CFF
$29.20 M
+$35.75 M+545.74%
December 31, 2024
Summary
- As of March 13, 2025, XLO annual cash flow from financing activities is $29.20 million, with the most recent change of +$35.75 million (+545.74%) on December 31, 2024.
- During the last 3 years, XLO annual CFF has fallen by -$231.47 million (-88.80%).
- XLO annual CFF is now -88.80% below its all-time high of $260.67 million, reached on December 31, 2021.
Performance
XLO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$8.20 M
+$8.21 M+273500.00%
December 31, 2024
Summary
- As of March 13, 2025, XLO quarterly cash flow from financing activities is $8.20 million, with the most recent change of +$8.21 million (+273500.00%) on December 31, 2024.
- Over the past year, XLO quarterly CFF has increased by +$9.84 million (+601.96%).
- XLO quarterly CFF is now -94.34% below its all-time high of $144.89 million, reached on March 31, 2021.
Performance
XLO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$29.20 M
+$9.84 M+50.81%
December 31, 2024
Summary
- As of March 13, 2025, XLO TTM cash flow from financing activities is $29.20 million, with the most recent change of +$9.84 million (+50.81%) on December 31, 2024.
- Over the past year, XLO TTM CFF has increased by +$35.75 million (+545.74%).
- XLO TTM CFF is now -88.80% below its all-time high of $260.67 million, reached on December 31, 2021.
Performance
XLO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
XLO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +545.7% | +602.0% | +545.7% |
| 3 y3 years | -88.8% | +602.0% | +545.7% |
| 5 y5 years | -51.4% | +602.0% | +545.7% |
XLO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -88.8% | +545.7% | -92.9% | +466.8% | -88.8% | +545.7% |
| 5 y | 5-year | -88.8% | +545.7% | -94.3% | +466.8% | -88.8% | +545.7% |
| alltime | all time | -88.8% | +545.7% | -94.3% | +466.8% | -88.8% | +545.7% |
Xilio Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $29.20 M(-545.7%) | $8.20 M(<-9900.0%) | $29.20 M(+50.8%) |
| Sep 2024 | - | -$3000.00(-100.0%) | $19.36 M(+13.0%) |
| Jun 2024 | - | $20.04 M(+2000.9%) | $17.13 M(-538.3%) |
| Mar 2024 | - | $954.00 K(-158.4%) | -$3.91 M(-40.3%) |
| Dec 2023 | -$6.55 M(+9392.8%) | -$1.63 M(-26.9%) | -$6.55 M(+32.7%) |
| Sep 2023 | - | -$2.24 M(+125.4%) | -$4.94 M(+81.3%) |
| Jun 2023 | - | -$992.00 K(-41.2%) | -$2.72 M(+55.4%) |
| Mar 2023 | - | -$1.69 M(+7938.1%) | -$1.75 M(+2439.1%) |
| Dec 2022 | -$69.00 K | -$21.00 K(-4.5%) | -$69.00 K(-100.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$22.00 K(+4.8%) | $115.78 M(-0.3%) |
| Jun 2022 | - | -$21.00 K(+320.0%) | $116.10 M(+0.3%) |
| Mar 2022 | - | -$5000.00(-100.0%) | $115.77 M(-55.6%) |
| Dec 2021 | $260.67 M(+2499.1%) | $115.83 M(>+9900.0%) | $260.67 M(+80.0%) |
| Sep 2021 | - | $301.00 K(-186.2%) | $144.84 M(+0.2%) |
| Jun 2021 | - | -$349.00 K(-100.2%) | $144.54 M(-0.2%) |
| Mar 2021 | - | $144.89 M | $144.89 M |
| Dec 2020 | $10.03 M(-83.3%) | - | - |
| Dec 2019 | $60.02 M | - | - |
FAQ
- What is Xilio Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Xilio Therapeutics?
- What is Xilio Therapeutics annual CFF year-on-year change?
- What is Xilio Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Xilio Therapeutics?
- What is Xilio Therapeutics quarterly CFF year-on-year change?
- What is Xilio Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Xilio Therapeutics?
- What is Xilio Therapeutics TTM CFF year-on-year change?
What is Xilio Therapeutics annual cash flow from financing activities?
The current annual CFF of XLO is $29.20 M
What is the all time high annual CFF for Xilio Therapeutics?
Xilio Therapeutics all-time high annual cash flow from financing activities is $260.67 M
What is Xilio Therapeutics annual CFF year-on-year change?
Over the past year, XLO annual cash flow from financing activities has changed by +$35.75 M (+545.74%)
What is Xilio Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of XLO is $8.20 M
What is the all time high quarterly CFF for Xilio Therapeutics?
Xilio Therapeutics all-time high quarterly cash flow from financing activities is $144.89 M
What is Xilio Therapeutics quarterly CFF year-on-year change?
Over the past year, XLO quarterly cash flow from financing activities has changed by +$9.84 M (+601.96%)
What is Xilio Therapeutics TTM cash flow from financing activities?
The current TTM CFF of XLO is $29.20 M
What is the all time high TTM CFF for Xilio Therapeutics?
Xilio Therapeutics all-time high TTM cash flow from financing activities is $260.67 M
What is Xilio Therapeutics TTM CFF year-on-year change?
Over the past year, XLO TTM cash flow from financing activities has changed by +$35.75 M (+545.74%)